Key Developments: Salix Pharmaceuticals Ltd (SLXP.OQ)

SLXP.OQ on NASDAQ Stock Exchange Global Select Market

116.76USD
10:45am EST
Price Change (% chg)

$1.84 (+1.60%)
Prev Close
$114.92
Open
$115.18
Day's High
$116.86
Day's Low
$114.92
Volume
24,576
Avg. Vol
695,706
52-wk High
$172.97
52-wk Low
$86.00

Search Stocks

Latest Key Developments (Source: Significant Developments)

Salix Pharmaceuticals Ltd announces important topline results for microbiome, culture & susceptibility, and key secondary efficacy results for TARGET 3, Rifaximin IBS-D Repeat treatment study
Monday, 11 Aug 2014 02:00pm EDT 

Salix Pharmaceuticals Ltd:Says topline results from analysis of microbiome, culture and susceptibility, and two key secondary efficacy endpoints from data collected in TARGET 3-Phase 3 randomized, double-blind, placebo-controlled study.To evaluate efficacy and safety of repeat treatment with rifaximin 550 mg TID (three times daily) for 14 days in subjects with irritable bowel syndrome with diarrhea, or IBS-D, who respond to initial treatment course with rifaximin 550 mg TID for 14 days.  Full Article

Salix Pharmaceuticals Ltd announces FDA assigns Sept. 29, Prescription Drug User Fee Act Goal Date for RELISTOR
Monday, 11 Aug 2014 07:00am EDT 

Salix Pharmaceuticals Ltd:Food and Drug Administration (FDA or Agency) has informed Salix that supplemental New Drug Application (sNDA) for RELISTOR(methylnaltrexone bromide) Subcutaneous Injection, 20 mg/ml.Says for treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain has been assigned user fee goal date of Sept. 29.  Full Article

Salix Pharmaceuticals Ltd gives Q3 2014 guidance below analysts' estimates; reaffirms FY 2014 guidance
Thursday, 7 Aug 2014 04:04pm EDT 

Salix Pharmaceuticals Ltd:Expects Q3 2014 total net product revenue of about $395.0 million.Expects Q3 2014 EBITDA, excluding expenses associated with the acquisition of Santarus and the pending merger with Cosmo Technologies, of about $155.0 million.Expects Q3 2014 Non-GAAP net income of about $121.0 million, or $1.53 per diluted share.Expects FY 2014 total net product revenue of about $1.6 billion.Expects FY 2014 EBITDA, excluding expenses associated with the acquisition of Santarus and the pending merger with Cosmo Technologies, of about $650 million.Expects FY 2014 non-GAAP net income of about $475 million, or $6.16 per diluted share.Q3 2014 revenue of $437 million, EBITDA of $172 million, net income of $135 million and EPS of $1.78 - Thomson Reuters I/B/E/S.FY 2014 revenue of $1.6 billion, EBITDA of $690 million, net income of $489 million and EPS of $6.53 - Thomson Reuters I/B/E/S.  Full Article

Salix Pharmaceuticals and Pharming Group NV announces FDA approval of RUCONEST for treatment of acute angioedema attacks in patients with Hereditary Angioedema
Thursday, 17 Jul 2014 01:00am EDT 

Salix Pharmaceuticals Ltd and Pharming Group NV:Says that the Food and Drug Administration has approved RUCONEST (C1 Esterase Inhibitor) 50 IU/kg for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema.Says because of the limited number of patients with laryngeal attacks, effectiveness was not established in HAE patients with laryngeal attacks.  Full Article

Salix Pharmaceuticals to combine with Cosmo Technologies to form Salix Pharmaceuticals plc
Tuesday, 8 Jul 2014 05:00pm EDT 

Salix Pharmaceuticals Ltd:Says the company and Cosmo Pharmaceuticals S.p.A. announced a definitive merger agreement under which Salix will combine with Cosmo Technologies Limited (Cosmo Tech), a subsidiary of Cosmo.Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Cosmo Tech, which will change its name to Salix Pharmaceuticals, plc and is expected to have its ordinary shares listed and traded on the NASDAQ Global Select Market.Transaction is expected to be modestly accretive to Salix's earnings per share in 2016 and increasingly accretive thereafter.  Full Article

Salix Pharmaceuticals Ltd reaffirms FY 2014 guidance; gives Q2 2014 guidance in line with analysts' estimates
Thursday, 8 May 2014 04:02pm EDT 

Salix Pharmaceuticals Ltd:Continues to expect FY 2014 total net product revenue of about $1.6 billion.Continues to expect FY 2014 EBITDA, excluding expenses associated with the acquisition of Santarus, of about $650 million.Continues to expect FY 2014 Non-GAAP net income of about $475 million, or $6.33 per diluted share.Expects Q2 2014 total net product revenue of about $395.0 million.Expects Q2 2014 EBITDA, excluding expenses associated with the acquisition of Santarus, of about $152.7 million.Expects Q2 2014 Non-GAAP net income of about $120.3 million, or $1.63 per diluted share.FY 2014 revenues of $1.6 billion, EBITDA of $672 million, net income of $482 million and EPS of $6.59 - Thomson Reuters I/B/E/S.Q2 2014 revenues of $393 million, EBITDA of $159 million, net income of $125.9 million and EPS of $1.71- Thomson Reuters I/B/E/S.  Full Article

Salix Pharmaceuticals Ltd and Progenics Pharmaceuticals announces acceptance of submission to expand use of RELISTOR in Chronic Non-Cancer Pain
Tuesday, 22 Apr 2014 07:00am EDT 

Salix Pharmaceuticals Ltd and Progenics Pharmaceuticals Inc:Submission to European Medicines Agency (EMA) of RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, has been accepted for review.If approved, this will add to current marketing authorization in European Union (EU), which allows for use of RELISTOR in advanced illness patients.  Full Article

Salix Pharmaceuticals Inc reaffirms FY 2014 outlook - Conference Call
Tuesday, 11 Mar 2014 04:30pm EDT 

Salix Pharmaceuticals Inc:Expects FY 2014 revenue of $1.6 bln.Expects FY 2014 EBITDA of $650 mln.FY 2014 revenue of $1.6 bln - Thomson Reuters I/B/E/S.  Full Article

Salix Pharmaceuticals Ltd gives FY 2014 guidance; EPS guidance above analysts' estimates; Q1 2014 guidance above analysts' estimates - Conference Call
Thursday, 27 Feb 2014 04:02pm EST 

Salix Pharmaceuticals Ltd:Sees FY 2014 product revenue to be about $1.6 bln.Sees FY 2014 non-GAAP fully diluted EPS to be $6.46.Q1 2014 revenue to be about $373 mln.Q1 2014 non-GAAP fully diluted EPS to be $0.85.FY 2014 revenues of $1.6 bln and EPS of $5.98 - Thomson Reuters I/B/E/S.Q1 2014 revenues of $370 mln and EPS $1.35 - Thomson Reuters I/B/E/S.  Full Article

Salix Pharmaceuticals Ltd and RedHill Biopharma announces worldwide license agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
Thursday, 27 Feb 2014 07:43am EST 

Salix Pharmaceuticals Ltd and RedHill Biopharma Ltd:Enters into exclusive agreement.Salix has licensed worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.Financial terms of transaction include upfront payment of $7 mln and $5 mln in subsequent payments to RedHill.  Full Article

Exclusive: Paulson & Co takes stake in Salix on heels of inventory issues - sources

- Hedge fund Paulson & Co has taken a stake in specialty pharmaceuticals company Salix Pharmaceuticals Ltd as the company recovers from inventory issues and the departure of its chief financial officer, according to people familiar with the matter.

Search Stocks